カテゴリ： GlobalData, アメリカ, 企業調査

Gemphire Therapeutics Inc (GEMP)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Gemphire Therapeutics Inc (GEMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9979
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：72
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Gemphire Therapeutics Inc (Gemphire), formerly Michigan Life Therapeutics LLC, is a clinical stage biopharmaceutical company that develops and commercializes therapies for patients with cardiometabolic disorders, including dyslipidemia and non-alcoholic steatohepatitis (NASH). Its lead product, Gemcabene (CI-1027), which is licensed from Pfizer is an oral therapy that targets known lipid metabolic pathways, lowering levels of LDL-C, inflammation and triglycerides. The company is evaluating gemcabene in clinical trials to enhance the clearance of very low-density lipoproteins (VLDLs) and to and inhibit the production of fatty acids and cholesterol in the liver. Gemphire is headquartered in Livonia, Michigan, the US.

Gemphire Therapeutics Inc (GEMP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Gemphire Therapeutics Raises USD5 Million in Financing Round 11
Gemphire Therapeutics Raises USD5 Million in Series A Financing Round 12
Merger 13
Michigan Life Therapeutics Merges with Gemphire Therapeutics 13
Equity Offering 14
Gemphire Therapeutics Prices Public Offering of Shares for USD22 Million 14
Gemphire Therapeutics Plans to Raise up to USD26 Million in Public Offering of Shares 16
Gemphire Therapeutics Raises USD12.5 Million in Private Placement of Units 17
Gemphire Therapeutics Raises USD30 Million in IPO 18
Gemphire Therapeutics Raises USD1.5 Million in Private Placement of Shares 20
Debt Offering 21
Gemphire Therapeutics Raises USD5 Million in Private Placement of Notes 21
Gemphire Therapeutics Raises USD0.2 Million in Private Placement of Notes 22
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 23
Gemphire Therapeutics Raises USD2.8 Million in Private Placement of Notes 24
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 25
Gemphire Therapeutics Inc – Key Competitors 26
Gemphire Therapeutics Inc – Key Employees 27
Gemphire Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Aug 13, 2018: Gemphire Therapeutics reports second quarter 2018 financial results and provides corporate update 29
May 08, 2018: Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 31
Mar 15, 2018: Gemphire Therapeutics Announces Fourth Quarter And Fiscal Year 2017 Financial Results 33
Nov 13, 2017: Gemphire Therapeutics Reports Third Quarter 2017 Financial Results 35
Aug 14, 2017: Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update 37
May 09, 2017: Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update 39
Mar 15, 2017: Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update 41
Corporate Communications 44
May 03, 2018: Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer 44
May 30, 2017: Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch 45
Mar 29, 2017: Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 46
Product News 47
02/27/2018: Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease and NASH to be Rescheduled 47
02/21/2018: Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease and NASH 48
Clinical Trials 50
Jan 31, 2018: Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease 50
Jan 17, 2018: Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia Patients 52
Dec 21, 2017: Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program 53
Nov 13, 2017: Gemphire Therapeutics Presents Data at American Heart Association Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population 55
Oct 23, 2017: Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting 2017 56
Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit 57
Sep 19, 2017: Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development 59
Sep 14, 2017: Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene 62
Aug 07, 2017: Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients 63
Jun 28, 2017: Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients 64
May 01, 2017: Gemphire to Present at ATVB|PVD 2017 Scientific Sessions 66
Mar 21, 2017: Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization 67
Jan 30, 2017: Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial 68
Jan 09, 2017: Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study 70
Jan 05, 2017: Gemphire Therapeutics Provides Clinical Update 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gemphire Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Gemphire Therapeutics Raises USD5 Million in Financing Round 11
Gemphire Therapeutics Raises USD5 Million in Series A Financing Round 12
Michigan Life Therapeutics Merges with Gemphire Therapeutics 13
Gemphire Therapeutics Prices Public Offering of Shares for USD22 Million 14
Gemphire Therapeutics Plans to Raise up to USD26 Million in Public Offering of Shares 16
Gemphire Therapeutics Raises USD12.5 Million in Private Placement of Units 17
Gemphire Therapeutics Raises USD30 Million in IPO 18
Gemphire Therapeutics Raises USD1.5 Million in Private Placement of Shares 20
Gemphire Therapeutics Raises USD5 Million in Private Placement of Notes 21
Gemphire Therapeutics Raises USD0.2 Million in Private Placement of Notes 22
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 23
Gemphire Therapeutics Raises USD2.8 Million in Private Placement of Notes 24
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 25
Gemphire Therapeutics Inc, Key Competitors 26
Gemphire Therapeutics Inc, Key Employees 27

List of Figures
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Gemphire Therapeutics Inc (GEMP)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Qenos Pty Ltd：企業の戦略的SWOT分析
    Qenos Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Seair Inc：企業の戦略的SWOT分析
    Seair Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Macquarie Group Ltd：企業の戦略・SWOT・財務情報
    Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Unique Catering & Management Services Ltd：企業の戦略・SWOT・財務情報
    Unique Catering & Management Services Ltd - Strategy, SWOT and Corporate Finance Report Summary Unique Catering & Management Services Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Cathay Pacific Airways Limited：企業のM&A・事業提携・投資動向
    Cathay Pacific Airways Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cathay Pacific Airways Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • NovaDigm Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary NovaDigm Therapeutics Inc (NovaDigm) is a developer of immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial diseases. The company’s products include NDV-3 vaccines, ALS3 vaccines, vaccine clinical supplies, bacterial and fungal vaccine antigens, vaginal …
  • Skanska AB (SKA B)：企業の財務・戦略的SWOT分析
    Skanska AB (SKA B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Arup Group Ltd：企業の戦略的SWOT分析
    Arup Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Charkit Chemical Corp：戦略・SWOT・企業財務分析
    Charkit Chemical Corp - Strategy, SWOT and Corporate Finance Report Summary Charkit Chemical Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • BB&T Corporation：企業のM&A・事業提携・投資動向
    BB&T Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BB&T Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Inova Health System：医療機器：M&Aディール及び事業提携情報
    Summary Inova Health System (Inova) is a non-profit health care delivery system. It owns owns, operates and manages several research, educational, clinical and hospital facilities. It offers home health and long term care services, joint replacement services, liver disease services, mental health se …
  • Airgas, Inc.：企業のM&A・事業提携・投資動向
    Airgas, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Airgas, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Haldia Petrochemicals Ltd：企業の戦略的SWOT分析
    Haldia Petrochemicals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Endo International Plc (ENDP)：企業の財務・戦略的SWOT分析
    Endo International Plc (ENDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Leroy Seafood Group ASA：企業の戦略・SWOT・財務情報
    Leroy Seafood Group ASA - Strategy, SWOT and Corporate Finance Report Summary Leroy Seafood Group ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BioMark Diagnostics Inc：医療機器：M&Aディール及び事業提携情報
    Summary BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company that owns and develops multiple intellectual properties in detection and quantitation of metabolites. The company’s advanced near-to- market diagnostic technologies designed to improve patient outc …
  • Kinross Gold Corp：企業の戦略・SWOT・財務情報
    Kinross Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Kinross Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Iksuda Therapeutics Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based t …
  • Tessco Technologies Incorporated (TESS)：企業の財務・戦略的SWOT分析
    Tessco Technologies Incorporated (TESS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Qc Holdings Inc：企業の戦略・SWOT・財務分析
    Qc Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Qc Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆